Clinico-histopathologic and single-nuclei RNA-sequencing insights into cardiac injury and microthrombi in critical COVID-19
Authors:
- Michael I. BrenerMBMichael I. Brener
- Michelle L. HulkeMHMichelle L. Hulke
- Nobuaki FukumaNFNobuaki Fukuma
- Stephanie GolobSGStephanie Golob
- Robert S. ZilinyiRZRobert S. Zilinyi
- Zhipeng ZhouZZZhipeng Zhou
- Christos TzimasCTChristos Tzimas
- Ilaria RussoIRIlaria Russo
- Claire McGroderCMClaire McGroder
- Ryan D. PfeifferRPRyan D. Pfeiffer
- Alexander ChongACAlexander Chong
- Geping ZhangGZGeping Zhang
Open Access
- 25 January 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (2)
Abstract
Acute cardiac injury is prevalent in critical COVID-19 and associated with increased mortality. Its etiology remains debated, as initially presumed causes — myocarditis and cardiac necrosis — have proved uncommon. To elucidate the pathophysiology of COVID-19–associated cardiac injury, we conducted a prospective study of the first 69 consecutive COVID-19 decedents at CUIMC in New York City. Of 6 acute cardiac histopathologic features, presence of microthrombi was the most commonly detected among our cohort. We tested associations of cardiac microthrombi with biomarkers of inflammation, cardiac injury, and fibrinolysis and with in-hospital antiplatelet therapy, therapeutic anticoagulation, and corticosteroid treatment, while adjusting for multiple clinical factors, including COVID-19 therapies. Higher peak erythrocyte sedimentation rate and C-reactive protein were independently associated with increased odds of microthrombi, supporting an immunothrombotic etiology. Using single-nuclei RNA-sequencing analysis on 3 patients with and 4 patients without cardiac microthrombi, we discovered an enrichment of prothrombotic/antifibrinolytic, extracellular matrix remodeling, and immune-potentiating signaling among cardiac fibroblasts in microthrombi-positive, relative to microthrombi-negative, COVID-19 hearts. Non–COVID-19, nonfailing hearts were used as reference controls. Our study identifies a specific transcriptomic signature in cardiac fibroblasts as a salient feature of microthrombi-positive COVID-19 hearts. Our findings warrant further mechanistic study as cardiac fibroblasts may represent a potential therapeutic target for COVID-19–associated cardiac microthrombi.Keywords
All Related Versions
Funding Information
- American Heart Association (COVID-19 Rapid Response Grant 814632)
- Columbia University - Cardiovascular Research Foundation (Columbia Cardiovascular COVID-19 Research Program)
- National Institutes of Health (T32HL007343)
- National Institutes of Health (K01HL140187)
- National Institutes of Health (UL1TR001873)
- U.S. Department of War (W81XWH2110217)
- Columbia University (Herbert)
- Columbia University (Florence Irving Scholars Program)
- the Japan Heart Foundation (Overseas Study Abroad Grant)
This publication has 61 references indexed in Scilit:
- Haemostasis and innate immunity – a complementary relationshipBritish Journal of Haematology, 2017
- Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosisNature Communications, 2017
- Brief Myocardial Ischemia Produces Cardiac Troponin I Release and Focal Myocyte Apoptosis in the Absence of Pathological Infarction in SwineJACC: Basic To Translational Science, 2017
- Genetic lineage tracing defines myofibroblast origin and function in the injured heartNature Communications, 2016
- Characterization of RNA isolated from eighteen different human tissues: results from a rapid human autopsy programCell and Tissue Banking, 2016
- Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarctionJournal of Molecular and Cellular Cardiology, 2015
- Profiling of RNA Degradation for Estimation of Post Morterm IntervalPLOS ONE, 2013
- Myofibroblast contraction activates latent TGF-β1 from the extracellular matrixJournal of Cell Biology, 2007
- Myocarditis. A histopathologic definition and classification.1987
- Early enzyme release from myocardial cells is not due to irreversible cell damage*Journal of Molecular and Cellular Cardiology, 1984